MADISON, EDWIN L,NGUYEN, JACK,RUGGLES, SANDRA WAUGH,THANOS, CHRISTOPHER D
申请号：
NZ59519306
公开号：
NZ595193A
申请日:
2006.10.20
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
Patent No. 595193 Disclosed is the use of a modified non-complement protease, or a catalytically active portion thereof, for formulation of a medicament for inhibiting complement activation to effect treatment of an inflammatory disease or disorder, wherein: the non-complement protease, or catalytically active portion thereof, comprises modifications at an amino acid residue that is a determinant of specificity compared to an unmodified or scaffold protease the scaffold protease is an MT-SP1 protease or a catalytically active portion thereof the modified amino acid residue(s) increases one or both of specificity for a target substrate or activity towards a target substrate, wherein the target substrate is a complement protein and the non-complement protease, or a catalytically active portion thereof, when contacted with any one or more target substrates of a complement pathway, results in cleavage of the target substrate protein such that complement activation in a pathway comprising the target substrate is inhibited, whereby inhibition of complement activation leads to a reduction of inflammatory symptoms associated with the disease or disorder, thereby treating the disease or disorder .
